Picture of boy being examining by doctor at a tuberculosis sanatorium

Understanding our future through Open Access research about our past...

Strathprints makes available scholarly Open Access content by researchers in the Centre for the Social History of Health & Healthcare (CSHHH), based within the School of Humanities, and considered Scotland's leading centre for the history of health and medicine.

Research at CSHHH explores the modern world since 1800 in locations as diverse as the UK, Asia, Africa, North America, and Europe. Areas of specialism include contraception and sexuality; family health and medical services; occupational health and medicine; disability; the history of psychiatry; conflict and warfare; and, drugs, pharmaceuticals and intoxicants.

Explore the Open Access research of the Centre for the Social History of Health and Healthcare. Or explore all of Strathclyde's Open Access research...

Image: Heart of England NHS Foundation Trust. Wellcome Collection - CC-BY.

Open innovation in new drug research : the Indian perspective

Bhatnagar, Bhawani and Dörfler, Viktor and MacBryde, Jillian (2015) Open innovation in new drug research : the Indian perspective. In: 22nd EurOMA 2015, 2015-06-26 - 2015-07-01, University of Neuchâtel.

[img]
Preview
Text (Bhatnagar-etal-EUROMA2015-open-innovation-in-new-drug-research)
Bhatnagar_etal_EUROMA2015_open_innovation_in_new_drug_research.pdf
Accepted Author Manuscript

Download (402kB) | Preview

Abstract

This article sketches open innovation strategies pursued by eight Indian pharmaceutical firms and provides an account of strategic flexibility charted by firms in the wake of changes in the legislative environment. The findings examined through the lens of open innovation and dynamic capabilities identifies ‘technological competencies’ and ‘funding’ as two very important reasons, which push the traditionally closed R&D firms to pursue open innovation. Within the dynamic capabilities framework, the findings suggest that resources and competencies play a vital role in enabling open innovation in the complex new drug research setting.